981 related articles for article (PubMed ID: 21270815)
1. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
Toba H; Yoshida M; Tojo C; Nakano A; Oshima Y; Kojima Y; Noda K; Wang J; Kobara M; Nakata T
Hypertens Res; 2011 Apr; 34(4):521-9. PubMed ID: 21270815
[TBL] [Abstract][Full Text] [Related]
2. Different effects of L/N-type and L-type calcium channel blockers on the renin-angiotensin-aldosterone system in SHR/Izm.
Konda T; Enomoto A; Aritomi S; Niinuma K; Koganei H; Ogawa T; Nitta K
Am J Nephrol; 2009; 30(2):155-61. PubMed ID: 19325231
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the cardioprotective and renoprotective effects of the L/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneously-hypertensive rats.
Aritomi S; Harada E; Sugino K; Nishimura M; Nakamura T; Takahara A
Clin Exp Pharmacol Physiol; 2015 Apr; 42(4):344-52. PubMed ID: 25582553
[TBL] [Abstract][Full Text] [Related]
4. Antiproteinuric effect of cilnidipine in hypertensive Japanese treated with renin-angiotensin-system inhibitors - a multicenter, open, randomized trial using 24-hour urine collection.
Miwa Y; Tsuchihashi T; Ohta Y; Tominaga M; Kawano Y; Sasaguri T; Ueno M; Matsuoka H
Clin Exp Hypertens; 2010; 32(6):400-5. PubMed ID: 20828221
[TBL] [Abstract][Full Text] [Related]
5. Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.
Soeki T; Kitani M; Kusunose K; Yagi S; Taketani Y; Koshiba K; Wakatsuki T; Orino S; Kawano K; Sata M
Hypertens Res; 2012 Nov; 35(11):1058-62. PubMed ID: 22763473
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of L- and N-type calcium channel blocker on glucose and lipid metabolism and renal function in patients with hypertension and type II diabetes mellitus.
Masuda T; Ogura MN; Moriya T; Takahira N; Matsumoto T; Kutsuna T; Hara M; Aiba N; Noda C; Izumi T
Cardiovasc Ther; 2011 Feb; 29(1):46-53. PubMed ID: 20337636
[TBL] [Abstract][Full Text] [Related]
7. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
[TBL] [Abstract][Full Text] [Related]
8. Cilnidipine, but not amlodipine, ameliorates osteoporosis in ovariectomized hypertensive rats through inhibition of the N-type calcium channel.
Shimizu H; Nakagami H; Yasumasa N; Mariana OK; Kyutoku M; Koriyama H; Nakagami F; Shimamura M; Rakugi H; Morishita R
Hypertens Res; 2012 Jan; 35(1):77-81. PubMed ID: 21881574
[TBL] [Abstract][Full Text] [Related]
9. Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N(G)-nitro-L-arginine methyl ester-induced hypertensive rat aorta: vasoprotective effects beyond the blood pressure-lowering effects of amlodipine and manidipine.
Toba H; Nakagawa Y; Miki S; Shimizu T; Yoshimura A; Inoue R; Asayama J; Kobara M; Nakata T
Hypertens Res; 2005 Aug; 28(8):689-700. PubMed ID: 16392774
[TBL] [Abstract][Full Text] [Related]
10. Comparison of L-type and mixed L- and T-type calcium channel blockers on kidney injury caused by deoxycorticosterone-salt hypertension in rats.
Baylis C; Qiu C; Engels K
Am J Kidney Dis; 2001 Dec; 38(6):1292-7. PubMed ID: 11728963
[TBL] [Abstract][Full Text] [Related]
11. Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte.
Fan YY; Kohno M; Nakano D; Ohsaki H; Kobori H; Suwarni D; Ohashi N; Hitomi H; Asanuma K; Noma T; Tomino Y; Fujita T; Nishiyama A
J Hypertens; 2010 May; 28(5):1034-43. PubMed ID: 20411599
[TBL] [Abstract][Full Text] [Related]
12. Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study.
Ohishi M; Takagi T; Ito N; Terai M; Tatara Y; Hayashi N; Shiota A; Katsuya T; Rakugi H; Ogihara T
Hypertens Res; 2007 Sep; 30(9):797-806. PubMed ID: 18037772
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of cilnidipine and amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats.
Takatsu M; Hattori T; Murase T; Ohtake M; Kato M; Nashima K; Nakashima C; Takahashi K; Ito H; Niinuma K; Aritomi S; Murohara T; Nagata K
J Hypertens; 2012 Sep; 30(9):1845-55. PubMed ID: 22796710
[TBL] [Abstract][Full Text] [Related]
14. A new-generation N/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L type calcium channel blocker.
Konoshita T; Makino Y; Kimura T; Fujii M; Wakahara S; Arakawa K; Inoki I; Nakamura H; Miyamori I;
J Hypertens; 2010 Oct; 28(10):2156-60. PubMed ID: 20625317
[TBL] [Abstract][Full Text] [Related]
15. Benidipine, a dihydropyridine L-type/T-type calcium channel blocker, affords additive benefits for prevention of cardiorenal injury in hypertensive rats.
Yamamoto E; Kataoka K; Dong YF; Nakamura T; Fukuda M; Nako H; Ogawa H; Kim-Mitsuyama S
J Hypertens; 2010 Jun; 28(6):1321-9. PubMed ID: 20224431
[TBL] [Abstract][Full Text] [Related]
16. Renoprotective effect of the L/N-type calcium channel antagonist cilnidipine on puromycin aminonucleoside-induced nephrosis in rats.
Takashima K; Nishiyama C; Arisaka N; Takahashi T; Souma S; Tsuda M; Hayashi M; Kasahara H; Kodama H; Tamura T; Murakami M; Kuroda J; Sato F
Arzneimittelforschung; 2009; 59(2):79-85. PubMed ID: 19338138
[TBL] [Abstract][Full Text] [Related]
17. Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.
Aritomi S; Niinuma K; Ogawa T; Konda T; Nitta K
Clin Exp Nephrol; 2013 Feb; 17(1):41-50. PubMed ID: 23011292
[TBL] [Abstract][Full Text] [Related]
18. Design and rationale of the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
Matsuoka H; Ando K; Ueshima K; Babazono T; Kario K; Tanaka S; Nakao K; Fujita T;
Clin Exp Hypertens; 2011; 33(7):455-62. PubMed ID: 21649534
[TBL] [Abstract][Full Text] [Related]
19. Renal and vascular protective effects of cilnidipine in patients with essential hypertension.
Morimoto S; Yano Y; Maki K; Iwasaka T
J Hypertens; 2007 Oct; 25(10):2178-83. PubMed ID: 17885563
[TBL] [Abstract][Full Text] [Related]
20. Involvement of N-type Ca(2+) channels in the fibrotic process of the kidney in rats.
Mishima K; Maeshima A; Miya M; Sakurai N; Ikeuchi H; Hiromura K; Nojima Y
Am J Physiol Renal Physiol; 2013 Mar; 304(6):F665-73. PubMed ID: 23324177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
